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To the Editor:
We read with interest the study by
Grewal and coworkers1 suggesting a
maturation defect of the aortic
wall in patients with bicuspid aortic
valve (BAV). A number of recent
publications have addressed the
pathobiology of BAV-associated
aortopathy; however most of them
just vaguely concluded that BAV and
tricuspid aortic valve must have
different mechanisms driving aortic
dilatation. Grewal and coworkers1
are commendable for their effort to
define the nature of this difference.
Their data, however, are partially in
contrast with previous studies, with
which they failed to perform a critical
comparison. We have reported2
increased a-smooth muscle actin
messenger RNA expression and
only mildly and nonhomogeneously
increased overall protein levels, with
subintimal areas of a-smooth muscleThe Journalactin–positive cell loss. This relative
stability of the amount of a-smooth
muscle actin (in contrast with Grewal
and coworkers’ data1), coupled with
smoothelin decrease (not absence,
unlike in Grewal and coworkers’
results1) was consistent with other
studies both of samples from patients
and of experimental models of
aneurysm (discussed in our own
article2) and suggests a loss of
contractile-phenotype smooth muscle
cells and the emergence of a differen-
tiated myofibroblast line.
In our previously mentioned study,2
we selected BAV and tricuspid aortic
valve patients with aortic stenosis
with a maximal diameter less than 4
cm and analyzed both the concavity
and the convexity of the vessel
to minimize confounding factors
by distinguishing constitutive from
stress-induced changes. Some of the
authors among Grewal and coworkers
have previously borrowed in their
studies this protocol of sample
retrieval from different sites of each
aorta, first introduced by us,3 and
confirmed that aortic wall changes
are asymmetrically expressed with
BAV, suggesting a role for long-
standing flow and stress pattern
alterations in their development.
The change of smooth muscle cell
orientation from circumferential to
longitudinal direction that we
observed in the convexity2 is known
to occur in vessels submitted to altered
tensile strain. The undefined site of
sampling in the study of Grewal and
coworkers,1 conversely, could explain
these discrepancies.
Similarly, Grewal and coworkers1
stated that the aortic wall specimens
were obtained during full-root
stentless implantation in patients
with nondilated BAV,1 suggesting
that the BAV specimens were taken
from the root (sinuses of Valsalva)
instead of the ascending tubular tract
proper. Where were the aortic
specimens taken in the other patients,
also considering that BAV aortopathy
usually affects the ascending tract?of Thoracic and Cardiovascular SurgerHow was valve function in the 4
groups? Also, the mean diameters
per subgroup were not listed.1 Intimal
thickness data1 were at odds with
previous investigations2,4; could
different diameters between BAV
and tricuspid aortic valve subgroups
explain this?
The paradigms of flow-induced
remodeling share many mechanisms
with the vascular aging process,
including increased transforming
growth factor-b receptor II signaling,5
which has been evidenced in aortopa-
thies both with and without associated
BAV.2 Functionally, one of the early
signs of arterial aging is impaired
wall distensibility, which is known
to occur in the BAV aorta, even
before overt dilation. Thus with
the currently available data, an
hypothesis of defective wall matura-
tion is hardly sustainable without
ruling out the contribution of flow-
induced remodeling. A conceptually
opposite theory of premature aging
of the aortic wall, prompted by altered
biomechanical environment, could be
drawn as well.
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We thank Drs Forte and Della Corte
for their insightful comments and the
opportunity to clarify a number of
points from our work. We agree with
the authors of the letter that the mecha-
nisms driving aortic dilation in bicuspid
aortic valve (BAV) and tricuspid aortic
valve (TAV) are different but not as yet
explained. Along that line, also based
on the expertise of most of our authors,
we hypothesized that a developmental
background linking BAV and the
accompanying aortic wall might
provide new insights into the matter.
Hemodynamic differences could still
play a role in the developing patho-
biology but might not be the primary
insult.
This approach led to different
selection criteria for our patient
population. We did not primarily
take into account the presence
of aortic stenosis/regurgitation but
focused on nondilation (<45 mm)
and dilation of the aortic wall within
the BAV and TAV groups. Additional
characteristics of our study population
are presented in Table 1, which
also provides answers to a number
of questions with regard to the
material studied. The aortic valve pa-
thology in nondilated and dilated
BAV and dilated TAV varied between
either stenosis or no stenosis, with or
without regurgitation. In dilated
BAV and TAV, in some cases only an2440 The Journal of Thoracic andascending aorta replacement was
performed because there was no aortic
root pathology that needed surgical
correction. All biopsy specimens
were taken from the ascending
aortic wall adjoining the surgical
transverse aortotomy site. In case of
post mortem or transplant material,
the tissue was taken at identical
sites. The results of Forte and col-
leagues1 and our publication2 can in
part be appreciated as complementary.
Some differences need an additional
explanation from our side, as provided
here.
The described results in expression
of a-smooth muscle actin in the article
of Forte and colleagues1 and our study
do indeed not correlate. This is
most probably due to a difference
of technique in which messenger
RNA expression based on reverse
transcriptase polymerase chain
reaction analysis of the vascular
wall1 was compared with our
immunohistochemical examination
of the 3 vessel wall layers.2 In
case of increased messenger RNA
detection, a lowered translation into
protein can not be excluded. Drs Forte
and Della Corte are correct that
almost absent smoothelin expression
cannot be detected by immuno-
histochemical means, so we agree
with their results that smoothelin
expression is lowered, which
correlates with an immature smooth
muscle cell phenotype.3,4 With
regard to the cellular composition of
the media and intima of the aortic
wall, we do not postulate a few
resident fibroblasts to be present that,
under experimental development of
thoracic aortic dilation, replace the
disappearing smooth muscle cell
population by myofibroblasts, as
indicated by Jones and associates5
and accepted by Forte and
colleagues.1 In our studies, it suffices
to have a mature contractile smooth
muscle cell phenotype that can switch
to a synthetic (immature) phenotype
that expresses most of the markersCardiovascular Surgery c November 20also attributed to the myofibroblast
phenotype, including the fibronectin
splice variants.6 Our assumption
is supported by less apoptosis
(caspase-3) in the wall of the nondi-
lated as well as the dilated BAV
(unpublished data). Apoptosis was,
however, detected (not shown) in the
media of the dilated TAV and was in
our study2 linked to the increased
expression of progerin. Regarding
this aspect, we will have further
comments when discussing the aspect
of aging.
As described previously, our study
population was primarily not selected
on the valve pathology or on the
difference in architecture of the
convex versus concave site. The fact
that our group consisted of patients
with a nondilated versus a dilated
aortic wall, with variable aortic
valve pathology and commissure
position, underlines that the observed
differences between all BAVs and
TAVs are intrinsic to the BAV wall
morphology. This is further supported
in a recently accepted article7 in
which we did address the differences
between the convex and concave
aortic sites of patients with a dilated
aortic wall, provided by our
German coauthors who have adopted
the selection technique described
previously.8 We did not disclaim the
earlier published differences8,9 in the
structure of the wall and the
expressions of markers between
the convex and concave site of
the aorta. We did, however perform,
an additional analysis on these
specimens with transforming growth
factor-b and endothelial nitric oxide
and found no difference in
expression between the convex and
concave sites.7 Hemodynamic influ-
ences are therefore not excluded
from having an important influence
but according to our studies cannot
be considered as the primary source
for the observed differences in
dilation formation between BAV
and TAV.14
